Alpine Immune Sciences

Alpine Immune Sciences EBIT per Share

Delisted

The EBIT per Share of Alpine Immune Sciences (ALPN) as of Nov 17, 2026 is -0.89 USD. In the previous year, EBIT per Share was -1.76 USD — a change of -49.77% (higher).

EBIT per Share

-0.89USD

YoY

-49.77%

Last updated:

EBIT per Share of Alpine Immune Sciences is 2023 -0.89 USD. EBIT per Share of Alpine Immune Sciences was 2022 -1.76 USD. It decreases by -49.77% higher compared to the previous year.

The Alpine Immune Sciences EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2022
-1.76 USD
Jan 1, 2023
-0.89 USD
Jan 1, 2024 (e)
-2.23 USD
Jan 1, 2025 (e)
-0.29 USD
Jan 1, 2026 (e)
-0.17 USD
Jan 1, 2027 (e)
-0.92 USD
Jan 1, 2028 (e)
-3.05 USD
Jan 1, 2029 (e)
0.00 USD
The Alpine Immune Sciences EBIT per Share history
YEAREBIT per ShareYoY
est0.00USD-100.00%
est-3.05USD+230.50%
est-0.92USD+440.09%
est-0.17USD-40.92%
est-0.29USD-87.03%
est-2.23USD+151.69%
-0.89USD-49.77%
-1.76USD-11.66%
-1.99USD+45.69%
-1.37USD-43.45%
-2.42USD-10.41%
-2.70USD+8.27%
-2.50USD-92.18%
-31.90USD+226.40%
-9.77USD+53.90%
-6.35USD-5.17%
-6.70USD+69.19%
-3.96USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alpine Immune Sciences Stock analysis

What does Alpine Immune Sciences do? Alpine Immune Sciences Inc. is a biopharmaceutical company specializing in the research and development of immunotherapies. Founded in 2015, the company is based in Seattle, Washington and holds numerous patents in the field of immunology. Alpine's business model is to utilize clinical science and innovative technologies to revolutionize immunotherapy. The company combines antibodies and other immunological agents to significantly improve the effectiveness and safety of therapies. The company is divided into several divisions, each offering different products and services. One division focuses on the discovery of novel antibodies and other biological agents. Through various technology platforms, Alpine continuously develops groundbreaking therapies that have the potential to revolutionize the treatment of cancer, autoimmune diseases, and other illnesses. Another division of Alpine is dedicated to the field of immuno-oncology, specifically researching and developing immunotherapies against cancer. The main goal is to enhance the body's own immune defenses against cancer cells. Furthermore, Alpine also develops therapies for specific autoimmune diseases, where the body's immune system attacks its own cells and tissues. In this area as well, the company relies on combining different immunological agents to increase the effectiveness and safety of the therapy. One of Alpine's most well-known products is ALPN-101, a novel antibody that can be used in immunotherapy against cancer and autoimmune diseases. This antibody has the potential to improve the effectiveness and safety of existing therapies, contributing to the cure and relief of illnesses. Alpine Immune Sciences Inc. has an impressive track record, having made significant progress in the field of immunotherapy in a short period of time and establishing itself as a leading provider of innovative therapies. Additionally, Alpine has successfully formed partnerships with other companies and institutions to advance its research and development. Overall, Alpine Immune Sciences Inc. represents a forward-thinking and innovative approach to immunotherapy, with the potential to change the lives of millions of people worldwide. Alpine Immune Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpine Immune Sciences stock

EBIT per Share of Alpine Immune Sciences is -0.89 USD in 2023.

EBIT per Share of Alpine Immune Sciences changed from -1.76 USD to -0.89 USD, representing a -49.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Alpine Immune Sciences since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Alpine Immune Sciences

All Key Metrics — Alpine Immune Sciences